First-In-Class Regenerative
Cell and Gene Therapies
Targeting Vascular Disease
ABOUT US
Ambulero, Inc is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease.
​
Our cell therapy program uses stromal cells engineered to express a cell adhesion molecule called E-selectin. We call these “supercharged” stromal cells because in animal models they promote exceptional tissue repair. For our gene therapy program, we simplify the approach by using established gene therapy vectors to give injured tissues the E-selectin molecule directly.
DRUG PIPELINE
Ambulero is developing a pipeline of candidate regenerative products engineered to provide a new approach for healing tissues damaged by vascular disease. We are developing two treatment modalities: one that delivers E-selectin as part of an engineered stromal cell (“Supercharged MSCs”) and the other delivering E-selectin as a gene therapy (AAV) vector.
MEDIA CENTER
July 22, 2024
AAV Gene Therapy Shows Promise for Preventing Limb and Tissue Loss: New Findings from Ambulero’s Chief Scientific and Medical Officers Published in the Annals of Surgery. Ambulero is excited to announce groundbreaking findings published in the Annals of Surgery. Lead investigators, Omaida C. Velazquez, MD, FACS and Zhao-Jun Liu, MD, PhD, along with co-investigators from the University of Miami and the University of Florida’s Powell Gene Therapy Center, report on a promising vascular regeneration gene therapy (exclusively licensed to Ambulero) that could salvage diseased ischemic limbs and one day eliminate the need for amputation.
NEW BUSINESS DEVELOPMENT
We believe our approach for repairing tissues damaged by vascular disease can offer patients new hope in the fight against vascular disease. Our first indication is a rare form of vascular ischemia that predominately strikes young patients and for which there is no satisfactory standard of care for many except limb amputation.
​
As Ambulero develops its cell and gene therapy products for treatment of selected vascular disease indications, we also seek research and partnering opportunities to maximize the value of our gene and cell therapies.
For questions or inquiries about collaborations and partnering, please contact:
​
Carlton Anderson
Chief Operating Officer
​
​